Skip to main content
Jonathan Talamo, MD, Ophthalmology, Waltham, MA

JonathanTalamoMD

Ophthalmology Waltham, MA

Cataract Related, Cornea & External Disease, Refractive Surgery

Director, Massachusetts Eye and Ear Waltham; Associate Professor of Ophthalmology, Part Time, Harvard Medical School

Dr. Talamo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Talamo's full profile

Already have an account?

  • Office

    1601 Trapelo Rd
    Ste 184
    Waltham, MA 02451
    Phone+1 781-890-1023
    Fax+1 781-890-2507

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Ophthalmology, 1986 - 1990
  • California Pacific Medical Center
    California Pacific Medical CenterInternship, Internal Medicine, 1986 - 1987
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1986

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1990 - 2025
  • RI State Medical License
    RI State Medical License 1991 - 1997
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
  • Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Ripple Therapeutics Appoints Jonathan Talamo, M.D., to Board of Directors
    Ripple Therapeutics Appoints Jonathan Talamo, M.D., to Board of DirectorsMay 4th, 2021
  • Johnson & Johnson Vision Wins FDA Nod for iDesign Lasik Device
    Johnson & Johnson Vision Wins FDA Nod for iDesign Lasik DeviceJune 18th, 2018
  • Ocular Therapeutix Touts Data from Phase III Trial of Dextenza
    Ocular Therapeutix Touts Data from Phase III Trial of DextenzaJanuary 4th, 2017
  • Join now to see all

Professional Memberships